Related Experiment Video

Updated: Nov 13, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.8K

Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders

Piyush Gediya1, Palak K Parikh2, Vivek K Vyas1

  • 1Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad, 382481, Gujarat, India.

European Journal of Medicinal Chemistry
|March 14, 2021
PubMed

Insights

Histone deacetylase 2 (HDAC2) plays a key role in cancer and neurodegenerative diseases. Developing selective HDAC2 inhibitors offers a promising therapeutic strategy with improved safety and efficacy for these conditions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Histone deacetylases (HDACs) are implicated in various diseases, including cancer, cardiovascular disorders, diabetes mellitus, neurodegenerative disorders, and inflammation.
  • Epigenetic alterations are central to diseases like cancer, driving progress in developing isoform-selective HDAC inhibitors.
  • Isoform-specific HDAC inhibitors offer improved safety profiles and reduced adverse events compared to non-selective agents.

Purpose of the Study:

  • To review the role of HDAC2 in the progression of cancer and neurodegenerative disorders.
  • To explore drug development opportunities for selective HDAC2 inhibition.

Main Methods:

  • Literature review of HDAC2's role in disease.
  • Analysis of current drug development strategies for selective HDAC2 inhibitors.

Main Results:

  • HDAC2 is significantly involved in the pathogenesis of cancer and neurodegenerative disorders.
  • Selective HDAC2 inhibition presents a viable therapeutic avenue with potential for reduced side effects.

Conclusions:

  • Targeting HDAC2 specifically holds significant therapeutic potential for treating cancer and neurodegenerative diseases.
  • Further development of selective HDAC2 inhibitors is warranted to address unmet medical needs.
Keywords:
CancerEpigenetic mutationHDAC inhibitorsHDAC2Histone deacetylases (HDACs)Neurodegenerative disorders

More Related Videos

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

21.8K
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.5K

Related Concept Videos

Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
8.9K
Histone Modification02:32

Histone Modification

4.0K
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
15.0K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
16.7K